Nuvoli Susanna, Palumbo Barbara, Malaspina Simona, Madeddu Giuseppe, Spanu Angela
Unit of Nuclear Medicine, Department of Clinical and Experimental Medicine, University of Sassari, Viale San Pietro 8, 07100 Sassari, Italy.
Hell J Nucl Med. 2018 Jan-Apr;21(1):60-68. doi: 10.1967/s002449910707. Epub 2018 Mar 20.
Nuclear medicine procedures are widely used as "in vivo" biomarkers in a large number of brain diseases, especially in the diagnosis of Parkinson's disease (PD) and of parkinsonian disorders (pD). Furthermore, nuclear medicine is used in the differential diagnosis of dementias especially Alzheimer's disease (AD) and dementia with Lewy's bodies (LBD) which share many clinical symptoms and often LBD is misdiagnosed as AD. The differential diagnosis between these clinical entities is crucial for treatment since LBD also shares some clinical symptoms with parkinsonian disorders. We reviewed the most relevant papers that study the usefulness of both iodine-123-ioflupane studied by single photon emission tomography (I-ioflupane SPET) and of I-metaiodobenzylguanidine (I-MIBG) cardiac scintigraphy in the diagnosis of PD and pD and in the differential diagnosis between AD and LBD in order to contribute to the clinical practice of the diseases.
核医学检查作为“体内”生物标志物在大量脑部疾病中广泛应用，尤其是在帕金森病（PD）和帕金森综合征（pD）的诊断中。此外，核医学用于痴呆症的鉴别诊断，特别是阿尔茨海默病（AD）和路易体痴呆（LBD），这两种疾病有许多共同的临床症状，LBD常被误诊为AD。这些临床实体之间的鉴别诊断对治疗至关重要，因为LBD也与帕金森综合征有一些共同的临床症状。我们回顾了最相关的论文，这些论文研究了通过单光子发射断层扫描（I-ioflupane SPET）研究的碘-123-ioflupane和I-间碘苄胍（I-MIBG）心脏闪烁显像在PD和pD诊断以及AD和LBD鉴别诊断中的作用，以便为这些疾病的临床实践提供帮助。
